Clinical Trials | April 08, 2026
Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
The trial also demonstrated significant improvements across multiple secondary endpoints
The trial also demonstrated significant improvements across multiple secondary endpoints
Immediate U.S. launch planned for Farxiga®-equivalent diabetes drug; opportunity pegged at $10.2 billion in annual market size
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
India’s first prospective study finds molecular testing improved diagnostic clarity in 50% of complex sarcoma cases
Participants also experienced a VR-enabled learning environment designed to support clinical skill development in controlled, repeatable, and risk-free settings
EB-003 is Enveric’s lead neuroplastogen, a 5-HT2A / 5-HT1B dual-acting compound designed to promote neuroplastic changes
Collaboration to study integration of AI-enabled VR solutions into medical and nursing curricula
Institute signs four MoUs, launches two products and marks 75 years with renewed focus on lab-to-market commercialisation
Board approves five-year appointment, subject to shareholder nod through postal ballot
Paid-up equity capital rises to Rs 973.19 crore following allotment to eligible employees
Subscribe To Our Newsletter & Stay Updated
